These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37190983)

  • 41. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
    Front Immunol; 2021; 12():665133. PubMed ID: 33936103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients.
    Chen RL; Zhou JX; Cao Y; Li SH; Li YH; Jiang M; Lu DY; Li P; Lin LZ
    Immunotherapy; 2019 Dec; 11(17):1481-1490. PubMed ID: 31713453
    [No Abstract]   [Full Text] [Related]  

  • 44. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
    Luo H; Song G; Wang D; Li M; Dai N
    Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.
    Chen K; Wang X; Yang L; Chen Z
    Cancer Control; 2021; 28():1073274821997430. PubMed ID: 33618535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
    Ni X; Xing Y; Sun X; Suo J
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):211-222. PubMed ID: 31208922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer.
    Thawani R; Agrawal N; Taflin NF; Kardosh A; Chen EY
    Oncologist; 2023 Jan; 28(1):40-47. PubMed ID: 36130326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Expert consensus on PD-L1 expression testing in esophageal carcinoma in China].
    Xue LY; Li Y; Huang J; ; ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):291-297. PubMed ID: 37078210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
    Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
    Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials.
    Wankhede D; Hofman P; Grover S
    J Cancer Res Clin Oncol; 2023 May; 149(5):2179-2189. PubMed ID: 35984491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
    Okadome K; Baba Y; Yasuda-Yoshihara N; Nomoto D; Yagi T; Toihata T; Ogawa K; Sawayama H; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Cancer Sci; 2022 Feb; 113(2):399-410. PubMed ID: 34773342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Immunotherapy in Esophageal and Gastric Cancer.
    Dedecker H; Teuwen LA; Vandamme T; Domen A; Prenen H
    Clin Colorectal Cancer; 2023 Jun; 22(2):175-182. PubMed ID: 37005190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.